032sek
19,0 %
Date:2025-05-14Time:18:00:00Latest report:Q1-2025List:First NorthTicker:ANNX
Market Cap:171 msekEnterprise Value:125 msekNet Sales:- msekEarnings:-45,8 msekEmployees:0ISIN:SE0009664154

Ratios

10-year key figure history for Annexin turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Annexin with index and moving average MA50 and MA200.

Stockprice:0,32
MA50:0,31
MA200:0,46
Price/MA200:-31,1 %
RSI (14):60,3
Price/MA50:4,5 %

Description

Annexin Pharmaceuticals is a biotechnology company with development in the Annexin A5 area. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for the treatment of patients with damage and inflammation in the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment and production of Annexin A5. The company was founded in 2014 and is based in Stockholm.

Biotechnology